Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

FDMTBullishIndustry Newsnews

High materiality9/10

4D-150 2-Year PRISM data support wet AMD backbone therapy potential

Jul 18, 2026, 3:17 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive 2-year data validates durability and reduced injections, a core value driver for a backbone therapy. Near-term upside hinges on Phase 3 progression (4FRONT) and potential adoption by retina centers; risk remains until regulatory milestones are met.

AI summary

What happened, with direct paths to the underlying reporting

4D Molecular Therapeutics reported positive two-year PRISM Phase 2b results for 4D-150 in a broad wet AMD population, with durable visual acuity and anatomic control and substantial treatment-burden reductions. The 3E10 vg/eye dose was selected for Phase 3 4FRONT, signaling a near-term catalyst as anti-VEGF durability advances progress toward a potential single-administration backbone therapy.

2-year PRISM results show durable BCVA and CST control.
Single-dose 4D-150 demonstrates reduced treatment burden.
3E10 vg/eye chosen for 4FRONT Phase 3 trials.
87% burden reduction in recently diagnosed subgroup.
Safety profile remains favorable with no new safety signals.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

4D-150 2-Year PRISM data support wet AMD backbone therapy potential

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study